Standard
Ribavirin dosage in patients with HCV genotypes 2 and 3 who completed short therapy with peg-interferon alpha-2b and ribavirin. / Mangia, A.; Dalgard, O.; Minerva, N.; Verbaan, H.; Bacca, D.; Larsen, Helmer Ring; Copetti, M. ; Caretta, V.; Piazzollla, V.; Cozzolongo, R.; Mottola, L.; Andriulli, A.
In:
Alimentary Pharmacology and Therapeutics, Vol. 31, No. 12, 01.06.2010, p. 1346-53.
Research output: Contribution to journal › Journal article › Research › peer-review
Harvard
Mangia, A, Dalgard, O, Minerva, N, Verbaan, H, Bacca, D, Larsen, HR, Copetti, M, Caretta, V, Piazzollla, V, Cozzolongo, R, Mottola, L & Andriulli, A 2010, 'Ribavirin dosage in patients with HCV genotypes 2 and 3 who completed short therapy with peg-interferon alpha-2b and ribavirin', Alimentary Pharmacology and Therapeutics, vol. 31, no. 12, pp. 1346-53.
APA
Mangia, A., Dalgard, O., Minerva, N., Verbaan, H., Bacca, D., Larsen, H. R., Copetti, M., Caretta, V., Piazzollla, V., Cozzolongo, R., Mottola, L., & Andriulli, A. (2010). Ribavirin dosage in patients with HCV genotypes 2 and 3 who completed short therapy with peg-interferon alpha-2b and ribavirin. Alimentary Pharmacology and Therapeutics, 31(12), 1346-53.
Vancouver
Mangia A, Dalgard O, Minerva N, Verbaan H, Bacca D, Larsen HR et al. Ribavirin dosage in patients with HCV genotypes 2 and 3 who completed short therapy with peg-interferon alpha-2b and ribavirin. Alimentary Pharmacology and Therapeutics. 2010 Jun 1;31(12):1346-53.
Author
Mangia, A. ; Dalgard, O. ; Minerva, N. ; Verbaan, H. ; Bacca, D. ; Larsen, Helmer Ring ; Copetti, M. ; Caretta, V. ; Piazzollla, V. ; Cozzolongo, R. ; Mottola, L. ; Andriulli, A. / Ribavirin dosage in patients with HCV genotypes 2 and 3 who completed short therapy with peg-interferon alpha-2b and ribavirin. In: Alimentary Pharmacology and Therapeutics. 2010 ; Vol. 31, No. 12. pp. 1346-53.
Bibtex
@article{04488347fe1b45faaffc48b25f296e1e,
title = "Ribavirin dosage in patients with HCV genotypes 2 and 3 who completed short therapy with peg-interferon alpha-2b and ribavirin",
keywords = "Former Faculty of Pharmaceutical Sciences",
author = "A. Mangia and O. Dalgard and N. Minerva and H. Verbaan and D. Bacca and Larsen, {Helmer Ring} and M. Copetti and V. Caretta and V. Piazzollla and R. Cozzolongo and L. Mottola and A. Andriulli",
year = "2010",
month = jun,
day = "1",
language = "English",
volume = "31",
pages = "1346--53",
journal = "Alimentary Pharmacology and Therapeutics, Supplement",
issn = "0953-0673",
publisher = "Wiley-Blackwell",
number = "12",
}
RIS
TY - JOUR
T1 - Ribavirin dosage in patients with HCV genotypes 2 and 3 who completed short therapy with peg-interferon alpha-2b and ribavirin
AU - Mangia, A.
AU - Dalgard, O.
AU - Minerva, N.
AU - Verbaan, H.
AU - Bacca, D.
AU - Larsen, Helmer Ring
AU - Copetti, M.
AU - Caretta, V.
AU - Piazzollla, V.
AU - Cozzolongo, R.
AU - Mottola, L.
AU - Andriulli, A.
PY - 2010/6/1
Y1 - 2010/6/1
KW - Former Faculty of Pharmaceutical Sciences
M3 - Journal article
VL - 31
SP - 1346
EP - 1353
JO - Alimentary Pharmacology and Therapeutics, Supplement
JF - Alimentary Pharmacology and Therapeutics, Supplement
SN - 0953-0673
IS - 12
ER -
